4Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase Ⅲ trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol, 2001, 19: 1734-1742. 被引量：1
5Schiller JH, Harrington D, Belani CP, et al. For the Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 2002, 346: 92-98. 被引量：1
6Mill AB, Hoogstrsten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981, 47: 207-214. 被引量：1
7Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res, 2000, 9: 129-137. 被引量：1
8Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer, 1999, 79: 538-544. 被引量：1
9Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association for Cancer Research Clinical Reserarsh Award Lecture. Clin Cancer Res, 2000, 6: 747-753. 被引量：1
10Ciardiello F, Caputo R, Pomatico C, et al. Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa), a selective epidermal growth factor tyrosine kinase inhibitor. Clin Cancer Res, 2001, 7: 1459-1465. 被引量：1
7Atagi S,Kawahara M,Tamura T,et al.Standard thoracic radiotherapy with or without concurrent daily low dose carboplatin in elderly patients with locally advanced non.small celllung cancer:a phase III trial of the Japan Clinical Oncology Group(JCOG9812)[J].Jpn J CIin Oncol,2005,35:195-201. 被引量：1
